News Medical on MSN1d
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
manilatimes2d
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
EurekAlert!2d
Expanded research on COPD and metabolic syndrome would advance patient-centered care
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.
healthday on MSN10h
Childhood Smoking Ups COPD Risk
Young teens might think smoking makes them look cool, but it’s likely to take their breath away in adulthood, a new st ...
News Medical on MSN1d
Smoking before age 15 significantly increases risk of chronic lung disease
A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...
Low birth weight may increase risk for later COPD
Individuals in the lowest quintile of birth weight appear to have an increased risk for subsequent chronic obstructive ...
Childhood smoking increases a person’s risk of developing COPD
Childhood smoking before age 15 increases a person’s risk of developing chronic obstructive pulmonary disease (COPD), according to a new study.
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Early Smoking Could Be A Death Sentence For Teens—Risks Parents Must Know
Teens who start smoking before age 15 face a 27 per cent higher risk of developing chronic obstructive pulmonary disease ...
NOLA.com7d
Chronic lung disease rates increase in Louisiana, despite national rates remaining the same
In 2021,138,825 people died from COPD in the U.S., making it the sixth overall leading cause of death and the fifth ...
Pharmaceutical Technology11d
AZD-6793 by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
AZD-6793 is under clinical development by AstraZeneca and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).